Sebastien Hotte

Image006 4

Dr. Sebastien Hotte likes a challenge. That’s fortunate since, like all oncologists, he faces many challenges every day. “You’re dealing with a very serious illness, caring for patients at pivotal times in their lives. You have to create a rapport and build trust very quickly,” he says. “And you have to know your medicine very well.” The medicine Dr. Hotte specializes in is genitourinary cancer. That is cancer of the prostate, bladder, kidney and testicle. Ever since his early training in Ottawa, his residency in London, Ontario, and his post grad studies at McMaster University, Dr. Hotte has been involved in research. His projects include some significant clinical trials in developmental therapeutics (new anti-cancer drugs), but he is also very interested in translational research – research that translates the findings of basic science so it is applied quickly to medical practice. In the years ahead, Dr. Hotte is looking forward to contributing to the development of more personalized cancer treatments. These are treatments that have the best odds of being effective depending on the patient’s genetic makeup and the type and stage of their cancer. “The Escarpment Cancer Research Institute will anchor my research agenda and make it easier for me to collaborate with other like-minded investigators,” says Dr. Hotte. “We have a common vision and a common goal.”

Key Publications:

Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 May 3. [Epub ahead of print] PubMed PMID: 24788563.

Blumenstein B, Saad F, Hotte S, Chi KN, Eigl B, Gleave M, Jacobs C. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Cancer Med. 2013;2:468-77.

Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer. 2013;109:943-9.